



General Assembly

Amendment

February Session, 2016

LCO No. 3786



Offered by:

SEN. GERRATANA, 6th Dist.

REP. RITTER M., 1st Dist.

To: Subst. Senate Bill No. 129

File No. 429

Cal. No. 293

**"AN ACT REQUIRING A STUDY OF ABUSE-DETERRENT AND
NONABUSE-DETERRENT OPIOID ANALGESICS."**

1 Strike everything after the enacting clause and substitute the
2 following in lieu thereof:

3 "Section 1. (NEW) (*Effective January 1, 2017*) (a) As used in this
4 section, (1) "opioid analgesic" means a drug product that contains an
5 opioid agonist and is approved by the federal Food and Drug
6 Administration for the treatment of pain, whether in immediate release
7 or extended release form, and whether or not combined with other
8 drug substances to form a single drug product or dosage, and (2)
9 "abuse-deterrent opioid analgesic" means an opioid analgesic with
10 labeling that indicates the drug's abuse-deterrent properties are
11 expected to deter or reduce the abuse of such drug.

12 (b) Each insurance company, health care center, hospital service
13 corporation, medical service corporation, fraternal benefit society or
14 other entity that delivers, issues for delivery, renews, amends or

15 continues any individual health insurance policy providing coverage
16 of the type specified in subdivisions (1), (2), (4), (11), (12) and (16) of
17 section 38a-469 of the general statutes and that provides coverage for
18 prescription drugs shall provide coverage for at least one abuse-
19 deterrent opioid analgesic per opioid analgesic active ingredient.

20 (c) Notwithstanding subdivision (2) of subsection (a) and
21 subdivision (1) of subsection (b) of section 38a-510 of the general
22 statutes, no such company, center, corporation, society or other entity
23 shall require an insured to use a non-abuse-deterrent opioid analgesic
24 prior to using an abuse-deterrent opioid analgesic.

25 Sec. 2. (NEW) (*Effective January 1, 2017*) (a) As used in this section,
26 (1) "opioid analgesic" means a drug product that contains an opioid
27 agonist and is approved by the federal Food and Drug Administration
28 for the treatment of pain, whether in immediate release or extended
29 release form, and whether or not combined with other drug substances
30 to form a single drug product or dosage, and (2) "abuse-deterrent
31 opioid analgesic" means an opioid analgesic with labeling that
32 indicates the drug's abuse-deterrent properties are expected to deter or
33 reduce the abuse of such drug.

34 (b) Each insurance company, health care center, hospital service
35 corporation, medical service corporation, fraternal benefit society or
36 other entity that delivers, issues for delivery, renews, amends or
37 continues any group health insurance policy providing coverage of the
38 type specified in subdivisions (1), (2), (4), (11), (12) and (16) of section
39 38a-469 of the general statutes and that provides coverage for
40 prescription drugs shall provide coverage for at least one abuse-
41 deterrent opioid analgesic per opioid analgesic active ingredient.

42 (c) Notwithstanding subdivision (2) of subsection (a) and
43 subdivision (1) of subsection (b) of section 38a-544 of the general
44 statutes, no such company, center, corporation, society or other entity
45 shall require an insured to use a non-abuse-deterrent opioid analgesic
46 prior to using an abuse-deterrent opioid analgesic."

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2017</i>	New section
Sec. 2	<i>January 1, 2017</i>	New section